Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering and developing novel products for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through collaborative research agreements, license fees, and grants. Its lead candidate, indiplon (for insomnia), is in Phase III clinical trials in collaboration with Pfizer, Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 | Balance Sheet (Sep 30, 2003) |
|---|---|---|---|
| Total Revenues | $29,259 | $111,943 | - |
| Net Loss | $(9,834) | $(33,449) | - |
| Loss Per Share (Basic/Diluted) | $(0.31) | $(1.07) | - |
| Cash & Cash Equivalents | - | - | $123,820 |
| Short-term Investments | - | - | $318,957 |
| Total Current Assets | - | - | $464,374 |
| Total Current Liabilities | - | - | $115,274 |
| Long-term Debt | - | - | $19,105 |
| Accumulated Deficit | - | - | $(235,375) |
Cash Flow (Nine Months Ended Sep 30, 2003):
- Net cash provided by operating activities: $38,770
- Net cash used in investing activities: $(155,534)
- Net cash provided by financing activities: $196,271
Material Changes vs. Prior Period
- Revenue Surge: Total revenues for the nine months ended September 30, 2003, increased to $111.9 million from $14.2 million in the same period in 2002. This 689% increase is primarily driven by the Pfizer collaboration agreement, which contributed $77.3 million in sponsored development funding and $27.0 million in amortized license fees.
- Expense Growth: Research and development (R&D) expenses rose to $138.2 million (nine months 2003) from $67.4 million (nine months 2002), reflecting expanded clinical activities, particularly the indiplon Phase III program. General and administrative expenses increased to $15.2 million from $9.1 million.
- Improved Net Loss: Despite higher operating expenses, the net loss for the nine months decreased to $33.4 million from $55.7 million in the prior year, largely due to the significant revenue recognition from Pfizer.
- Balance Sheet Expansion: Total assets grew from $266.5 million (Dec 31, 2002) to $552.4 million (Sep 30, 2003). This was fueled by a $187.4 million equity offering in September 2003 and the consolidation of Science Park Center LLC, which added approximately $14.0 million in property and equipment (later offset by debt retirement).
- Deferred Revenue: Deferred revenues increased significantly to $80.6 million ($51.4M current + $29.2M non-current) from $6.5 million at year-end 2002, reflecting upfront payments received from Pfizer.
Outlook, Risks, and Management Commentary
- Guidance & Outlook: Management expects to continue incurring operating losses as R&D expenses increase. The company anticipates filing a New Drug Application (NDA) for indiplon in the first half of 2004. Capital resources are deemed sufficient for at least the next 12 months.
- Real Estate Transactions: The company is selling its current headquarters for approximately $40 million (expected Q4 2003 closing) and constructing a new facility. A gain of approximately $18.0 million is expected upon the sale closing. Construction of the new facility is expected to be completed in July 2004.
- Key Risks:
- Clinical Trial Failure: Success depends on the safety and efficacy of indiplon in Phase III trials. Failure would severely harm the business.
- Collaborator Dependence: The company relies heavily on Pfizer for funding and commercialization of indiplon. Pfizer can terminate the agreement with 180 days' notice.
- Regulatory Approval: No products are currently approved. Delays or rejections by the FDA could prevent revenue generation.
- Liquidity: While current cash is strong, the company has a history of losses and may require additional funding in the future.
- Legal Proceedings: An arbitration is ongoing with The Salk Institute regarding milestone payments for CRF antagonists. Management believes no additional payments are owed and expects no material adverse effect.
Investor Verification Checklist
- Pfizer Collaboration Status: Verify the specific terms of the Pfizer agreement, particularly the conditions for milestone payments and the risk of termination.
- Indiplon Clinical Data: Monitor upcoming Phase III clinical trial results and the timeline for the anticipated NDA filing in early 2004.
- Real Estate Closing: Confirm the closing of the current headquarters sale and the recognition of the projected $18.0 million gain in Q4 2003.
- Cash Burn Rate: Assess the sustainability of the current cash position ($442.8 million in liquid assets) against the projected increase in R&D and construction costs.
- Deferred Revenue Recognition: Review the amortization schedule for the $100 million upfront payment from Pfizer to understand future revenue visibility.